Finance

Lists
NGEN:NASDAQ
NervGen Pharma Corp
$1.57
-1.48%
(-0.024) 1D
Oct 19, 2:50:43 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for NGEN...
Open
$1.59
High
$1.61
Low
$1.53
Mkt. cap
168.43M
Avg. vol.
502.92K
Volume
314.59K
52-wk high
$6.30
52-wk low
$1.53
EPS
-$0.54
Beta
0.82
Shares outstanding
107.52M
No. of employees
10
Open
$1.59
High
$1.61
Low
$1.53
Mkt. cap
168.43M
Avg. vol.
502.92K
Volume
314.59K
52-wk high
$6.30
52-wk low
$1.53
EPS
-$0.54
Beta
0.82
Shares outstanding
107.52M
No. of employees
10
News stories
From web sources and news partners
About NervGen Pharma Corp
CEO-
Employees10
Founded2017
HeadquartersVancouver, British Columbia, Canada
SectorPharmaceutical industry
Websitenervgen.com
Analyst ratings
Based on 2 analysts giving stock ratings to NGEN in the past 3 months
Buy
Buy
2
Hold
0
Sell
0
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for NGEN in the last 3 months.
Highest
Current $1.57
$10.00 (+538.37%)
Average
$10.00 (+538.37%)
Lowest
$10.00 (+538.37%)
Analyst
Recommendation
Action
Price target
Projected
Date
Marc Goodman
Leerink Partners
Buy
Maintained
$10.00
+538.4%
10/01/2026
Joseph Thome
TD Cowen
Buy
Maintained
-
-
08/13/2026
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
$15.00
+857.5%
07/14/2026
Justin Keywood
Stifel Nicolaus
Buy
Reiterated
$6.00
+283%
05/21/2026
Elemer Piros
Lucid Capital
Buy
Initiated
$18.00
+1,049.1%
04/15/2026
Andre Uddin
Research Capital
Buy
Maintained
$5.50
+251.1%
04/10/2026
Michael Okunewitch
Maxim Group
Buy
Reiterated
$12.00
+666%
04/09/2026
Previous reportsAll values in CAD
Loading Previous Earnings...
Revenue
Net income
All values in CAD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
4.44M
3.60M
4.86M
7.89M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.73M
2.80M
2.67M
4.31M
Operating expense
6.17M
6.40M
7.53M
12.20M
Total operating expenses
6.17M
6.40M
7.53M
12.20M
Operating income
-6.17M
-6.40M
-7.53M
-12.20M
Other non operating income
1.98M
-20.24M
5.72M
-19.35M
EBT including unusual items
-4.16M
-26.91M
-1.68M
-29.22M
EBT excluding unusual items
-4.16M
-26.91M
-1.68M
-29.22M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-4.16M
-26.91M
-1.68M
-29.22M
Net profit margin
-
-
-
-
Earnings per share
-0.06
-
-
-
Interest and investment income
77.07K
61.68K
104.07K
180.45K
Interest expense
-
-
-
-
Net interest expenses
77.07K
61.68K
104.07K
180.45K
Depreciation and amortization charges
-
-
-
-
EBITDA
-6.16M
-6.39M
-7.52M
-12.18M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps